Resmetirom: all 23 studies that test it

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 FibrosisRecruitingNCT07848191Phase 4
• Resmetirom in Patients With MASH and HFpEFRecruitingNCT07830758Phase 1
• Study of Resmetirom in Children and Adolescents With MASHRecruitingNCT07763015Phase 2
• Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHRecruitingNCT07335601Phase 2
• Resmiterom Efficacy & Safety in Patients With MASHRecruitingNCT07249788Phase 4
• A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIVRecruitingNCT07143968Phase 2
• Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)CompletedNCT03038022Phase 2Results posted
• Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT02912260Phase 2Results posted
• A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult ParticipantsCompletedNCT07216313Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal FunctionCompletedNCT06397872Phase 1
• A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)Active, not recruitingNCT05500222Phase 3
• A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)Active, not recruitingNCT04951219Phase 3
• Drug Interaction Study of MGL-3196 With ClopidogrelCompletedNCT04671069Phase 1
• Drug Interaction Study of MGL-3196 With PioglitazoneCompletedNCT04671056Phase 1
• Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control SubjectsCompletedNCT04643795Phase 1
• A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease PatientsCompletedNCT04197479Phase 3
• A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and FibrosisActive, not recruitingNCT03900429Phase 3
• Bioavailability Study of MGL-3196 Tablets Compared to CapsulesCompletedNCT03413124Phase 1
• Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196CompletedNCT03220165Phase 1
• Drug Interaction Study of MGL-3196 With AtorvastatinCompletedNCT02749578Phase 1
• Drug Interaction Study of MGL-3196 With Rosuvastatin and SimvastatinCompletedNCT02542969Phase 1
• Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy SubjectsCompletedNCT01519531Phase 1
• Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy SubjectsCompletedNCT01367873Phase 1

← Resmetirom overview